Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (28)

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Correction to: SEOM‑GEMCAD‑TTD clinical guidelines for localized rectal cancer (2021) (Clinical and Translational Oncology, (2022), 24, 4, (646-657), 10.1007/s12094-022-02816-9)

    Clinical and Translational Oncology

  3. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 646-657

2020

  1. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

    Clinical and Translational Oncology, Vol. 22, Núm. 2, pp. 236-244

2019

  1. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 46-54

  2. Treatment and outcome of patients with stage is testicular cancer: A retrospective study from the Spanish germ cell cancer group

    Journal of Urology, Vol. 202, Núm. 4, pp. 742-747

2018

  1. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

    International Journal of Cancer, Vol. 143, Núm. 8, pp. 1954-1962

2017

  1. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

  2. Grupo español de tumores germinales (grupo germinal)

    Revisiones en Cancer, Vol. 31, Núm. 1, pp. 1-8

  3. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients

    Journal of the National Cancer Institute, Vol. 109, Núm. 4

2015

  1. Re: Mette Saksø Mortensen, Jakob Lauritsen, Maria Gry Gundgaard, et al. A nationwide cohort study of stage i seminoma patients followed on a surveillance program. Eur Urol 2014;66:1172-8

    European Urology

2014

  1. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

    Annals of Oncology, Vol. 25, Núm. 1, pp. 216-225

  2. Prognostic factors for relapse in stage I seminoma: A new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2173-2178

2013

  1. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study

    BMC Cancer, Vol. 13

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

  5. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. Risk-adapted treatment in clinical stage I testicular seminoma: The third Spanish Germ Cell Cancer Group study

    Journal of Clinical Oncology, Vol. 29, Núm. 35, pp. 4677-4681